Up-regulation of uncoupling protein 3 by thyroid hormone, peroxisome proliferator-activated receptor ligands and 9-cis retinoic acid in L6 myotubes  by Nagase, Itsuro et al.
Up-regulation of uncoupling protein 3 by thyroid hormone, peroxisome
proliferator-activated receptor ligands and 9-cis retinoic acid in L6
myotubes
Itsuro Nagasea, Shigeru Yoshidab, Xavier Canasa, Yukiko Iriea, Kazuhiro Kimuraa,
Toshihide Yoshidac, Masayuki Saitoa;*
aDepartment of Biomedical Sciences, Laboratory of Biochemistry, Graduate School of Veterinary Medicine, Hokkaido University,
Sapporo 060-0818, Japan
bPharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba 305-8566, Japan
cFirst Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
Received 2 September 1999; received in revised form 22 October 1999
Abstract Uncoupling protein 3 (UCP3), expressed abundantly
in the skeletal muscle, is one of the carrier proteins dissipating
the transmitochondrial electrochemical gradient as heat, and
thereby has been implicated in the regulation of energy
metabolism. We have investigated UCP3 mRNA expression in
the widely used L6 myocyte cell line by Northern blot analysis.
UCP3 mRNA was not detected in L6 myoblasts, but appeared
after their differentiation to myotubes. The UCP3 mRNA level
was increased when L6 myotubes were treated with increasing
concentrations of triiodothyronine (T3), oleic acid, K-bromopal-
mitate and carbacyclin, a non-selective ligand of peroxisome
proliferator-activated receptors (PPARs), whereas it was not
influenced when treated with selective ligands of PPARK (WY
14 643) and PPARQ (troglitazone). A ligand of retinoid X
receptor (RXR), 9-cis retinoic acid, was also effective by itself
and in combination with carbacyclin in stimulating UCP3
mRNA expression. The mRNA analysis of individual PPAR
isoforms revealed that L6 cell expressed a significant level of
PPARN but undetectable levels of PPARK and PPARQ. These
results suggest that UCP3 expression in myocytes is differentia-
tion-dependent and regulated by the T3 receptor, RXR and
PPARN.
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1. Introduction
Uncoupling proteins (UCPs) are a family of mitochondrial
transporters that dissipate the transmitochondrial proton gra-
dient more as heat than via ATP synthesis. UCP1, a classical
UCP, is present exclusively in brown adipose tissue, which is
the major site of regulatory thermogenesis during cold expo-
sure and voluntary hyperphagia in small rodents. It is well
accepted that the activity and gene expression of UCP1 are
controlled synergistically by triiodothyronine (T3) and nore-
pinephrine released from sympathetic nerves [1,2]. Recently,
two isoforms of UCP, UCP2 and UCP3, were identi¢ed in
rodents and man, based on their similarity to UCP1 [3^5].
Since these new UCPs have been reported to reduce the mi-
tochondrial potential when overexpressed in vitro, they may
have uncoupling activity, and thereby plausibly be involved in
the regulation of whole-body thermogenesis and energy ex-
penditure. Particularly interesting is that UCP3 is expressed
mainly in skeletal muscle, which is thought to be the major
thermogenic organ in larger mammals, including humans. In
fact, several reports showed that the gene expression of muscle
UCP3 altered remarkably under various physiological and
pathological conditions related to energy metabolism (for re-
view, see [6]). For example, the UCP3 mRNA level in skeletal
muscle is increased during fasting and decreased by refeeding
[7^9]. T3 treatment also induces a marked rise in the UCP3
mRNA level [7,10]. However, cold exposure, which is the
most e¡ective physiological stimulus to induce UCP1 expres-
sion, does not in£uence UCP3 expression [4,8,10].
Despite the increasing number of reports on UCP3, the
molecular and/or cellular mechanisms regulating UCP3 ex-
pression in skeletal muscle are still poorly understood. This
is largely because most studies were carried out in vivo, not in
vitro, thus making it di⁄cult to identify stimulatory or inhib-
itory factors directly acting in muscle cells. In the present
study, we examined UCP3 mRNA expression in a widely
used myocyte cell line L6, and demonstrated that UCP3 ex-
pression in myocytes was up-regulated by T3, ligands of
PPAR, and retinoid X receptor (RXR).
2. Materials and methods
2.1. Cell culture
Rat muscle L6 cells (clone L6Y) were kindly provided by Dr. Amira
Klip (Programme in Cell Biology, The Hospital for Sick Children,
Toronto, Ont., Canada). They were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum
(FCS), 50 units/ml penicillin and 50 Wg/ml streptomycin. When the
cells reached con£uence (Day 0), a medium containing 2% horse se-
rum, 50 units/ml penicillin and 50 Wg/ml streptomycin (di¡erentiation
medium) was used for cell di¡erentiation. The fresh di¡erentiation
medium was substituted at Day 4, and after 2^3 h test substances
dissolved in 0.1% DMSO were added. After a 24-h culture, the cells
were harvested for RNA extraction.
2.2. Northern blot and RT-PCR analyses
Total RNA was extracted by the guanidium-thiocyanate method
[11] using ISOGEN (Nippon Gene, Toyama, Japan). For Northern
blot analysis, 30 Wg of total RNA was separated on a 1.2% agarose/
formaldehyde gel and transferred to and ¢xed on a nylon membrane.
DNA fragments used for hybridization probes were: a 924-bp PCR
product of the rat UCP3 cDNA [12], and a 452-bp PCR product of
the rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA.
They were labeled with [K-32P]dCTP using a multiprime DNA label-
ing kit (Amersham, Buckinghamshire, England). The blots were hy-
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bridized to the labeled cDNA probes in 0.5 M sodium phosphate (pH
6.8), 7% SDS, 1% BSA, 1 mM EDTA and 200 Wg/ml heat-denatured
salmon sperm DNA at 65‡C for 12 h, washed with 2USSC or
0.1USSC at 65‡C, and analyzed with a BAS 2000 bio-imaging ana-
lyzer (Fuji Film, Tokyo, Japan).
The mRNA level of PPAR isoforms was determined by real time
quantitative RT-PCR analysis as described previously [13]. Oligonu-
cleotide primers used were: PPARK, 5P-701GGCCTCAGGATAC-
CACTATGG-3P and 5P-761TCGCCGAAAGAAGCCC-3P ; PPARQ,
5P-1182CAGTGGAGACCGCCCAG-3P and 5P-1243GCAGGTTGT-
CTTGGATGTCC-3P ; PPARN, 5P-1278GCTGGTCGACAGTGATC-
TGG-3P and 5P-1338TGGCCGGTCTCCGC-3P. The reaction mixture
contained 1UTaqMan EZ bu¡er, 3 mM Mn(OAc)2, 300 WM dNTP,
2.5 units of rTth DNA polymerase, 200 nM primers, and 50 ng of
total RNA in 25 Wl. RT was carried out at 55‡C for 50 min, 60‡C for
10 min, 95‡C for 2 min for 1 cycle, and PCR at 95‡C for 15 s, and
58‡C for 1.5 min for 40 cycles on an ABI PRISM 7700 Sequence
Detector (Perkin-Elmer Applied Biosystems, Tokyo, Japan).
2.3. Chemicals
Sodium 3,5,3-triiodo-l-thyronine (T3), 9-cis retinoic acid, carbacy-
clin, and oleic acid were purchased from Sigma (St. Louis, MO,
USA), WY 14 643 [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic
acid from Cayman Chemical Co. (Ann Arbor, MI, USA), and
K-bromopalmitate (2-bromohexadecanoic acid) from Aldrich (Mil-
waukee, WI, USA). Troglitazone was a gift from Sankyo Pharmaceut-
icals Inc. (Tokyo, Japan).
3. Results
3.1. UCP3 mRNA expression in L6 cells
L6 myoblasts di¡erentiated morphologically to fuse into
myotubes when cultured in the presence of 2% horse serum
4^5 days after reaching con£uence. mRNA expression of
UCP3 was examined by Northern blot analysis at con£uence
and after di¡erentiation. As shown in Fig. 1, no signal of
UCP3 mRNA was detected at con£uence (Day 0), but at
4 and 7 days after di¡erentiation signi¢cant levels of UCP3
mRNA were observed, although they were much weaker than
those of rat skeletal muscle.
3.2. Stimulatory e¡ects of T3 and fatty acids on UCP3 mRNA
expression
It has been reported that the tissue mRNA level of UCP3 is
greatly increased in skeletal muscle by treating animals with
T3 [7,10] or with triglyceride (Intralipid) and heparin [14],
suggesting that T3 and fatty acids are potent inducers of
muscle UCP3. To con¢rm this in vitro, the e¡ects of T3
and fatty acids on UCP3 mRNA expression were examined
in L6 myotubes. As shown in Fig. 2, the addition of T3
increased the UCP3 mRNA level dose-dependently. Oleic
acid was also e¡ective in stimulating UCP3 expression at a
physiological concentration (100 WM). A similar stimulation
Fig. 1. Di¡erentiation-dependent expression of UCP3 mRNA in L6
cells. L6 myoblasts were cultured in DMEM containing 10% FCS,
and after reaching con£uence (Day 0) they were di¡erentiated to
myotubes in a medium containing 2% horse serum for 1^7 days.
Thirty Wg of total RNA was used for Northern blot analysis. As a
reference, 15 Wg of total RNA of rat skeletal muscle was also ana-
lyzed.
Fig. 2. Dose-dependent stimulation of UCP3 mRNA expression by
T3 and fatty acids in L6 myotubes. L6 myotubes were treated for
24 h with the vehicle (V), 0.1^10 WM T3, 1^100 WM oleic acid or
1^10 WM K-bromopalmitate (BrPl).
Fig. 3. Expression of PPAR isoforms and e¡ects of their ligands on
UCP3 mRNA expression in L6 myotubes. A: L6 myotubes were
treated with various concentrations of carbacyclin (cPGI), WY
14 643 (WY) or troglitazone (Trog) for 24 h. V, vehicle. B: mRNA
expression of individual PPAR isoforms was analyzed by RT-PCR
for L6 myoblasts (MB) and myotubes (MT).
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was seen with a much lower concentration (10 WM) of an
unmetabolizable fatty acid derivative, K-bromopalmitate.
3.3. E¡ects of PPAR ligands on UCP3 expression
Fatty acids including K-bromopalmitate are known as li-
gands of the PPAR [15], which are involved in the induction
of UCP1 and UCP2 in vivo and in vitro [2,16^18]. To con¢rm
the role of PPARs and to determine which PPAR subtype is
involved, we examined the e¡ects of various PPAR ligands on
UCP3 expression in L6 myotubes di¡erentiated for 4 days. L6
myotubes were cultured for 24 h with carbacyclin (non-selec-
tive PPAR ligand), WY 14 643 (PPARK ligand) or troglita-
zone (PPARQ ligand). When the cells were treated with 0.1^10
WM carbacyclin, the UCP3 mRNA level was increased dose-
dependently, whereas it was not in£uenced by WY 14 643 or
troglitazone even at 10 WM (Fig. 3A). We also examined the
e¡ects of the PPAR ligands in L6 cells di¡erentiated for
7 days, and obtained almost the same results (data not
shown). To examine expression of individual PPAR isoforms
in L6 cell, the RNA samples obtained from the cells before
and 4 days after di¡erentiation were analyzed by RT-PCR. As
shown in Fig. 3B, signi¢cant levels of PPARN mRNA were
present in both L6 myoblasts and myotubes, while neither
PPARK or PPARQ was detectable.
3.4. E¡ect of 9-cis retinoic acid on UCP3 mRNA expression
It is known that UCP1 expression in brown adipocytes is
induced by activation of RXR, by forming heterodimers with
PPARs [19]. We examined the e¡ect of 9-cis retinoic acid, a
ligand of RXR, on UCP3 expression in L6 myotubes. As
shown in Fig. 4A, the UCP3 mRNA level was increased by
increasing concentrations of 9-cis retinoic acid (0.1^10 WM).
The e¡ects of carbacyclin in the presence of 1 WM 9-cis reti-
noic acid were also examined (Fig. 4B). The UCP3 mRNA
level was up-regulated by carbacyclin in the presence of 9-cis
retinoic acid.
4. Discussion
In this study, we examined mRNA expression of UCP3 in
vitro using the widely used myocyte cell line L6. The major
¢ndings were: (1) L6 cells expressed UCP3 mRNA at a low
but signi¢cant level only after di¡erentiation from myoblasts
to myotubes, (2) UCP3 expression in L6 myotubes was in-
creased by the treatments with T3, and some ligands of
PPAR, and (3) UCP3 expression was enhanced further by
simultaneous treatment with 9-cis retinoic acid, a ligand of
RXR.
The present results clearly indicated that the expression of
UCP3 in myocytes was di¡erentiation-dependent. This seems
compatible with the abundant expression of skeletal muscle in
vivo. In fact, a recent analysis of a 7-kb 5P-£anking region of
the UCP3 gene revealed that the binding motif of MyoD, a
muscle-speci¢c transcription factor family, was most abun-
dant in this region [20]. Additionally, this region has one
thyroid hormone and three peroxisome proliferator response
elements. As expected, we demonstrated that T3 treatment
increased UCP3 mRNA dose-dependently in L6 myotubes,
con¢rming the stimulatory e¡ect of T3 on muscle UCP3 ex-
pression repeatedly reported in vivo. These results, together
with the e¡ects of T3 on UCP1, suggest that the thermogenic
and metabolic actions of T3 may be, at least in part, due to
the increased gene expression of UCP1 in brown adipose tis-
sue and UCP3 in skeletal muscle.
A possible role of fatty acids in muscle UCP3 expression
was initially suggested from in vivo studies. For example, the
UCP3 mRNA level in skeletal muscle is up-regulated when
the plasma fatty acid level is elevated by either fasting [7^
9,21,22] or co-infusion of triglyceride (Intralipid) and heparin
[14] in rodents and humans. In the present study, we found a
marked, dose-dependent increase in the UCP3 mRNA level in
L6 myotubes treated with oleic acid and also with K-bromo-
palmitic acid. This is well consistent with a recent report that
oleic acid induces UCP3 in another myocyte cell line, C2C12
[9]. Thus, fatty acids induce muscle UCP3 expression by act-
ing directly on myocytes. It is known that fatty acids can serve
as ligands of PPARs to transactivate some genes, including
those of the fatty acid metabolism [15]. Considering the pres-
ence of the peroxisome proliferator response element in the 5P-
£anking region of the UCP3 gene [20], it is quite likely that
the stimulatory action of fatty acids is mediated by PPARs.
Potential involvement of PPARs in UCP3 expression was fur-
ther con¢rmed by the observation that carbacyclin, a potent
non-selective PPAR ligand, greatly increased the UCP3
mRNA level. The mRNA analysis of individual PPAR iso-
forms revealed that L6 cell expressed a signi¢cant level of
PPARN but undetectable levels of PPARK and PPARQ.
Although carbacyclin is an e¡ective activator of all PPAR
isoforms, it may be the most e⁄cacious activator of PPARN
[23]. All these data suggest a predominant role of PPARN in
the activation of the UCP3 gene in L6 myocytes. In support
of this idea, neither WY 14 643 (PPARK ligand) nor troglita-
zone (PPARQ ligand) was e¡ective in UCP mRNA induction
in L6 myotubes. The ine¡ectiveness of troglitazone appears to
con£ict with recent reports that UCP3 expression was in-
Fig. 4. E¡ects of 9-cis retinoic acid on UCP3 mRNA in L6 myo-
tubes. L6 myotubes were treated for 24 h with: A: 0.1^10 WM 9-cis
retinoic acid (9-cis RA); B: 0.1 and 1 WM carbacyclin (cPGI) in the
presence or absence of 1 WM 9-cis retinoic acid. V, vehicle.
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creased by PPARQ ligands in C2C12 myocytes [9] and primary
cultured adipocytes [24]. The precise reason for such discrep-
ancies is not clear at present, but it would be attributable to
di¡erent expression levels of PPARQ among the cells.
It is well established that PPARs transactivate gene expres-
sion in the form of heterodimers with RXR. In the present
study, a ligand of RXR 9-cis retinoic acid, by itself and also in
combination with carbacyclin, increased the expression of
UCP3 mRNA. The stimulatory action of RXR has been dem-
onstrated for UCP1 expression in brown adipocytes, where
the RXR/PPARQ heterodimer plays a predominant role [2].
Our results suggest that UCP3 expression in L6 myocytes is
activated by the heterodimer of RXR with PPARN, and prob-
ably also by the RXR homodimer. To con¢rm this, more
detailed analysis of the regulatory mechanism of UCP3 gene
expression in myocyte is required by using cells transfected
with a reporter gene connected with the 5P-£anking region
of the UCP3 gene.
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